Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RadProtect in Healthy Volunteers
NCT02587442Phase 1Unknown
- Sponsor
- Original BioMedicals Co., Ltd.
- Start
- Oct 2015
- Primary completion
- Mar 2016
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RadProtect in Acute Radiation Syndrome (ARS), sponsored by Original BioMedicals Co., Ltd. Primary endpoint: Safety and tolerability profile including Dose Limiting Toxicity (DLT) at Day 28. Status: unknown.
02
Drugs
RadProtect
03
Conditions
Acute Radiation Syndrome (ARS)
Beyond the preview
Go deeper on NCT02587442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02587442.